Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
IN-VIVO THERAPEUTIC EFFECTS OF INTERLEUKIN-12 AGAINST HIGHLY METASTATIC RESIDUAL LYMPHOMA
Autore:
VERBIK DJ; STINSON WW; BRUNDA MJ; KESSINGER A; JOSHI SS;
Indirizzi:
UNIV NEBRASKA,MED CTR,DEPT ANAT & CELL BIOL,600 S 42ND ST OMAHA NE 68198 UNIV NEBRASKA,MED CTR,DEPT ANAT & CELL BIOL OMAHA NE 68198 HOFFMANN LA ROCHE INC,DEPT ONCOL NUTLEY NJ 07110 UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED OMAHA NE 68198
Titolo Testata:
Clinical & experimental metastasis
fascicolo: 3, volume: 14, anno: 1996,
pagine: 219 - 229
SICI:
0262-0898(1996)14:3<219:ITEOIA>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
HEMATOPOIETIC STEM-CELLS; ACTIVATED KILLER CELLS; SUCCESSFUL IMMUNOTHERAPY; MARROW TRANSPLANTATION; MATURATION FACTOR; RECONSTITUTION; PURIFICATION; LYMPHOCYTES; RECOVERY; MICE;
Keywords:
ANTITUMOR EFFECTS; IMMUNE AUGMENTATION; INTERLEUKIN-12; RESIDUAL LYMPHOMA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
31
Recensione:
Indirizzi per estratti:
Citazione:
D.J. Verbik et al., "IN-VIVO THERAPEUTIC EFFECTS OF INTERLEUKIN-12 AGAINST HIGHLY METASTATIC RESIDUAL LYMPHOMA", Clinical & experimental metastasis, 14(3), 1996, pp. 219-229

Abstract

Despite considerable advancement in anticancer therapy, minimal residual disease (MRD) is still a major problem in the clinical management of cancer, including lymphoma, In this report, we have studied the antitumor effects of interleukin-12 (IL-12) against an aggressive liver metastatic murine RAW117-H10 lymphoma. Our results using three different doses of IL-12 (0.175, 0.35 and 0.7 mu g/mouse) showed that a 0.35 mu g dose is the most efficacious against lymphoma grown in intact mice. Furthermore, we have evaluated the therapeutic effects of IL-12 against residual lymphoma in a transplantation setting. BALB/c mice were treated with high-dose therapy (HDT) and transplanted with syngeneic bone marrow cells added with a known number of RAW117-H10 lymphoma cellsto mimic the clinical situation of MRD. The mice were then treated with IL-12 (0.25 mu g/mouse/day) alone or IL-12 plus activated cytotoxiceffector cells, Our results showed that IL-12 had a significant (P<0.05) antitumor therapeutic effect against liver metastatic lymphoma grown in intact mice as well as in lymphoma-bearing mice treated with HDTfollowed by stem cell transplantation as determined by survival period. The therapeutic effect of IL-12 was also demonstrated by a very significant decrease (P<0.05) in the tumor burden in livers from the IL-12-treated mice. Mice that were treated with IL-12 following HDT and hematopoietic stem cell transplantation had a significant decrease in circulating white blood cells (P<0.05), a significant increase in spleenweight and cellularity (P<0.05), and hematopoietic progenitor cells (P<0.05), a significant increase in the number of splenocytes expressing IL-2 alpha-chain receptor (P<0.05), and an increase in the frequencyof natural killer cells in their spleens, These studies suggest that cytokines such as IL-12 may have the potential to mediate antitumor effects against residual lymphoma without compromising lymphohematopoietic recovery.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 15:15:56